Loading stock data…
$8.15-0.20 (-2.40%)
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.
Immix Biopharma, Inc. in the Healthcare sector is trading at $8.15 with a market capitalization of $990M. Wall Street consensus targets $24.43 (8 analysts), implying a +199.7% move over the next 12 months. The stock is currently 46% below its 52-week high of $15.10, remaining 13.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 28 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$12.46M↓ | -$10.80M↑ | -$10.89M↓ | -$7.66M↓ | -$6.72M |
| Net Income | -$11.56M↓ | -$10.09M↑ | -$10.69M↓ | -$7.59M↓ | -$6.62M |
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead prod...